Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates
10. August 2020 16:01 ET
|
Abeona Therapeutics Inc.
Additional patients dosed in RDEB, MPS IIIA and MPS IIIB clinical programs General alignment with CHMP on plans for EU registration of ABO-102 for MPS IIIA Data from RDEB and MPS III programs...
Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference
18. Mai 2020 08:01 ET
|
Seelos Therapeutics, Inc.
NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors
15. Mai 2020 10:30 ET
|
Seelos Therapeutics, Inc.
NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Receives Rare Pediatric Disease Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome
15. Mai 2020 07:30 ET
|
Seelos Therapeutics, Inc.
NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
12. Mai 2020 08:01 ET
|
Seelos Therapeutics, Inc.
NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)
04. Mai 2020 08:01 ET
|
Seelos Therapeutics, Inc.
NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Receives Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome
30. April 2020 13:31 ET
|
Seelos Therapeutics, Inc.
NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Provides Q1 2020 Business Update and Pipeline Developments
08. April 2020 09:01 ET
|
Seelos Therapeutics, Inc.
NEW YORK, April 08, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces Closing of Public Offering of Common Stock
16. März 2020 16:30 ET
|
Seelos Therapeutics, Inc.
NEW YORK, March 16, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces European Medicines Agency Guidance to Design an Open-Label Pivotal Study for SLS-005 in Sanfilippo Syndrome
11. März 2020 08:01 ET
|
Seelos Therapeutics, Inc.
NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...